Names and pronunciation
(ohl-sal′ah-zeen) Dipentum
PDF page 982
Loading InternPractice…
Drug reference
(ohl-sal′ah-zeen) Dipentum
PDF page 982
Func. class.: GI antiinflammatory
PDF page 982
Chem. class.: Salicylate derivative
PDF page 982
Do not confuse: olsalazine/OLANZapine
PDF page 982
ACTION: Bioconverted to 5-aminosali- cylic acid, which decreases inflammation
PDF page 982
USES: Maintenance of remission of ulcerative colitis in patients intolerant to sulfasalazine
PDF page 982
CONTRAINDICATIONS: Hyper- sensitivity to this product or salicylates Precautions: Pregnancy, breastfeeding, children <14 yr; impaired renal/hepatic function; severe allergy; bronchial asthma
PDF page 982
SIDE EFFECTS CNS: Headache, hallucinations, depres- sion, vertigo, fatigue, dizziness GI: Nausea, vomiting, abdominal pain, diarrhea, bloating INTEG: Rash, dermatitis, urticaria
PDF page 982
INTERACTIONS Increase: azaTHIOprine toxicity—aza- THIOprine Increase: myelosuppression—mercap- topurine, thioguanine Increase: bleeding risk—low-molecular- weight heparins; discontinue before using this product Increase: Reye’s syndrome develop- ment—varicella vaccine; do not use within 6 wk of olsalazine Increase: PT, INR—warfarin Drug/Lab Test Increase: AST, ALT
PDF page 982
DOSAGE AND ROUTES • Adult: PO 500 mg bid, max 3 g/day
PDF page 982
Available forms: Caps 250 mg
PDF page 982
Administer: • Total daily dose evenly spaced to mini- mize GI intolerance; give with food • Store in tight, light-resistant container at room temperature
PDF page 982
Assess: • Colitis: bowel pattern, number of stools, consistency, frequency, pain, mu- cus, abdominal pain before treatment and periodically • Allergic reaction: rash, dermatitis, ur- ticaria, pruritus, dyspnea, broncho- spasm; allergy to salicylates, sulfon- amides • BUN, creatinine in those with renal disease; LFTs (liver disease); monitor I&O, output of 1500 mL/day is needed to prevent crystals in urine • Pregnancy/breastfeeding: use only if benefits outweigh fetal risk; avoid breast- feeding, excreted in breast milk
PDF page 982
Evaluate: • Therapeutic response: absence of fe- ver, mucus in stools, decreased diarrhea, abdominal pain
PDF page 982
CLINICAL CONSIDERATIONS
PDF page 982
Patient and caregiver information: • To report diarrhea, rash, bleeding, bruising, fever, hallucinations, or if symp- toms do not improve after 2 mo of therapy • That product may cause dizziness; to avoid hazardous activities until reaction is known • To take even if feeling better; to take as directed; to take missed dose when re- membered, but not to double • That lab work and exams will be needed during treatment
PDF page 983
PHARMACOKINETICS Partially absorbed, peak 11⁄2 hr, half-life 30-90 min (rectal), 2-15 hr (PO), excreted in urine as 5-aminosalicylic acid and metabolites, crosses placenta
PDF page 982
• Adult: PO 500 mg bid, max 3 g/day
PDF page 982